Updates in Individualizing Therapy in Type 2 Diabetes: Optimizing Insulin and Non-Insulin Combinations

New Orleans, LA US

Sunday, March 24, 2019
Hilton New Orleans Riverside, Grand Ballroom AB
Registration/Breakfast: 5:30 – 5:45 am | Program: 5:45 – 7:45 am

This course is a live CME-certified Ancillary Symposium presented at ENDO 2019, held in New Orleans, LA. This educational activity is supported by an independent medical educational grant from Eli Lilly and Company through a collaboration between the Endocrine Society and Medscape Education. These ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).








Target Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners, and other healthcare professionals.


Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Compare and contrast the therapeutic characteristics, efficacy, and safety of ultra-long-acting basal insulins and faster-acting prandial insulins
  • Incorporate the emerging evidence into practice regarding combination of GLP-1 agonists and SGLT-2 inhibitors with other non-insulin diabetes therapies in treatment of type 2 diabetes
  • Address highly insulin resistant patients using concentrated insulins and combination therapies
  • Devise individualized treatment strategies for insulin and non-insulin diabetes therapies using current guidelines and up-to-date trial information

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Hilton New Orleans Riverside, Grand Ballroom AB
2 Poydras St
New Orleans, LA 70130
United States

Program Chair

Carol H. Wysham, MD
MultiCare Rockwood Clinic Diabetes & Endocrinology Center
Spokane, WA




John L. Leahy, MD
University of Vermont
Shelburne, VT


Wendy S. Lane, MD
Mountain Diabetes and Endocrine Center
Asheville, NC




The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Wendy S. Lane, MD: Advisory Board Member, Insulet Corporation, Novo Nordisk; Grant Recipient, Novo Nordisk; Research Investigator, Sanofi-Aventis, Novo Nordisk; Speaker, Novo Nordisk, Insulet Corporation
John Leahy, MD: Advisory Board Member, Janssen, Merck, Novo Nordisk, Valeritas; Research Support, Takeda
Carol H. Wysham, MD: Advisory Board Member, Abbott Laboratories, Insulet Corporation, Janssen, Novo Nordisk, Sanofi-Aventis; Advisory Board Member, Spouse, Lexicon Pharmaceuticals, Inc.; Speaker, AstraZeneca, Insulet Corporation, Jansen Pharmaceuticals, Novo Nordisk, Sanofi-Aventis


The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Beret Ann Casey, MD

The following SPC members reported relevant financial relationships:

Andrew Ahmann, MD: Research Support, Dexcom, Medtronic; Consultant, Dexcom, Eli Lilly & Company, Horizon CME, MannKind, Novo Nordisk, Sanofi; Speaker, Horizon CME; Principle Investigator, National Institute of Health, T1D Exchange, Trial Net
Giuseppe Barbesino, MD: Advisory Boards, Horizon Pharmaceuticals, Ipsen Pharmaceuticals; Spouse, employee of Genzyme
Joan Han, MD:Research Support, Rhythm Pharmaceuticals; Principle Investigator, Insys Therapeutics, Rhythm Pharmaceuticals
Steven T. Harris, MD:Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health
Jonathan Purnell, MD: Advisor, Novo Nordisk
Neda Rasouli, MD:Research Support, Novo Nordisk, Boehringer Ingelheim, Rhythm Pharmaceuticals, Elira Therapeutics; Consultant, Intarcia
Amy Rothberg, MD:Spouse, consultant of Merck
Susmeeta Sharma, MD: Speaker, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Deborah Sellmeyer, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Click "Start" to complete the meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™ and 2.0 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 


Review your Diplomate ABIM ID Number(s)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

Available Credit

  • 2.00 ABIM MOC
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation